Charles Schwab
AYTU icon

Charles Schwab’s AYTU BioPharma AYTU Stock Holding History

Charles Schwab’s Portfolio AYTU Stock Details AYTU Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-2,745
Closed -$418K – 3417
2021
Q1 		$418K Buy
2,745
+2,195
+399% +$348K ﹤0.01% 3138
2020
Q4 		$66K Hold
550
– – ﹤0.01% 3339
2020
Q3 		$131K Buy
550
+303
+123% +$77.9K ﹤0.01% 3230
2020
Q2 		$71K Buy
+247
New +$74.8K ﹤0.01% 3251

Other funds holding AYTU

AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Charles Schwab's AYTU Position: Q2 2021 in Review

Charles Schwab sold out of AYTU BioPharma (AYTU) in Q2 2021, closing a stake of 2,745 shares — an estimated $418K sold.

Charles Schwab first reported a position in AYTU in Q2 2020 and held it in 4 quarters. The position peaked at $418K in Q1 2021. 50 funds tracked by Wall St. Rank hold AYTU as of Q2 2021.

  • Charles Schwab reported no remaining AYTU BioPharma position as of Q2 2021 after selling out during the quarter.
  • Charles Schwab sold 2,745 AYTU BioPharma shares in Q2 2021, an estimated $418K.
  • Charles Schwab first reported a position in AYTU BioPharma in Q2 2020 and held it in 4 quarters.
  • Charles Schwab's AYTU BioPharma position peaked at $418K in Q1 2021.
  • 50 funds tracked by Wall St. Rank held AYTU BioPharma as of Q2 2021.

Based on Charles Schwab's 13F filing for Q2 2021, filed 16 Aug 2021.